Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of ALT-100 in Healthy Volunteers
NCT05426746Phase 1Completed
- Sponsor
- Aqualung Therapeutics
- Start
- Jul 2022
- Primary completion
- May 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in acute respiratory distress syndrome (ARDS) comparing ALT-100 with Placebo (2 arms). Primary endpoint: Incidence, frequency and dose-relationship of all adverse events up to 120 days. Started Jul 2022; status: completed.
02
Drugs
enamptcumab
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT05426746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05426746.